In a report published Wednesday, Morgan Stanley analyst Daniel Brennan initiated coverage on Bruker Corporation BRKR with an Overweight rating and $23.00 price target.
In the report, Morgan Stanley noted, “BRKR has a strong, technology oriented, analytical instrument franchise where mgmt historically focused almost exclusively on top line growth (less regard for margins and FCF). With significant new management hires/structure & incentives, we expect the company to execute on driving significant margin expansion and balance sheet/cash flow efficiency improvement. After growing ~8% CAGR over the past 5 years (14% past 7), BRKR is now focused on generating consistent profitable growth. With more disciplined investment and capital allocation, we expect revenue CAGR of 4-8% CAGR, still superior to peers.”
Bruker Corporation closed on Tuesday at $18.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in